Ofatumumab launch?

When was ofatumumab launched?

Ofatumumab (brand name Arzerra) was launched in the United States in 2009 for treatment of chronic lymphocytic leukemia (CLL). [1]

What was ofatumumab approved for at launch?

At launch, ofatumumab was approved for CLL in patients whose disease had progressed after prior therapies. [1]

Who makes ofatumumab, and is it still on the market?

Arzerra is marketed by Novartis. It remains an identified product in current drug information coverage, including patent and market-competition tracking. [1][2]

What to check next if you’re looking for “launch” details (approval timing vs. patent/exclusivity)

People searching “ofatumumab launch” often want one of two different time markers:
- First regulatory approval/launch (e.g., 2009 in the US) [1]
- Patent and exclusivity timelines that affect when competitors can enter

DrugPatentWatch.com tracks patent/exclusivity context for specific products, which can help if your real goal is “when do generics/biosimilars or other entrants arrive.” [2]

Sources

1. https://www.drugs.com/history/ofatumumab.html
   
2. https://www.drugpatentwatch.com/